S017 Consultative Dermatology for the Hospitalized Patient
DESCRIPTION
The ultimate goal of this session is to equip attendees with practical and immediately applicable skills for inpatient and consult work within the house of medicine. In this high-yield session, expert Dermatology Hospitalists will review some of the most common skin diseases seen in consultation. Topics include: pediatric emergencies, severe cutaneous adverse reactions, retiform purpura, hidradenitis suppurativa, tele-consults, and oncodermatologic emergencies. Information will be delivered in high-impact 20-minute specialty segments with an emphasis on practical practice points that are not readily available in the literature or textbooks.
LEARNING OBJECTIVES
Identify cutaneous manifestations of systemic diseases, medication reactions, and infections as they present in the hospitalized patient with skin disease.
Develop a working differential diagnosis, management plan, and treatment algorithm for hospitalized patients with skin disease.
Draw from a set of high-yield clinical pearls for performing inpatient and consultative dermatology care.
DIRECTOR
Helena Beth Pasieka, MD
SPEAKERS
Steven T. Chen, MD, MPH, FAAD
MassGeneral Brigham/Harvard Medical School
Colleen Cotton, MD, FAAD
Benjamin Kaffenberger, MD, MS, FAAD
Ohio State university
Robert Micheletti, MD, FAAD
Perelman School of Medicine, University of Pennsylvania
DISCLOSURES
Steven T. Chen, MD, MPH, FAAD
AbbVie – Advisory Board(Honoraria); Vertex Pharmaceuticals Incorporated – Employee (w-2 relationship)(Salary); VisualDx – Independent Contractor(Fees);
Colleen Cotton, MD, FAAD
Amgen – Investigator(Grants/Research Funding); CorEvitas – Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Galderma – Advisory Board(Honoraria); HS Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Inner Archways LLC – Advisory Board(Other Financial Benefit); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Consultant (1099 relationship)(No Compensation Received), Investigator(Grants/Research Funding); Pierre Fabre – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding);
Benjamin Kaffenberger, MD, MS, FAAD
Almirall – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant (1099 relationship)(Honoraria); HCW Biologics – Investigator(Grants/Research Funding); InflaRx – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Leo Pharma – Investigator(Grants/Research Funding); National Comprehensive Cancer Network – Speaker(Honoraria); Pfizer Inc. – Data Safety Monitoring Board(Fees); Protillion Biosciences – Consultant (1099 relationship)(Stock Options);
Robert Micheletti, MD, FAAD
Boehringer Ingelheim – Investigator(Grants/Research Funding); Cabaletta Bio – Investigator(Grants/Research Funding); Vertex Pharmaceuticals, Inc. – Consultant(Fees);
Helena Beth Pasieka, MD
No financial relationships exist with ineligible companies.